Bio-Techne Corporation
Profit after direct costs
Core business profitability
Bottom line profitability
Top line growth rate
Flow of revenue through cost categories to net income
| Item | Trend | 2022 | 2023 | 2024 | 2025 | 2026 | YoY Change |
|---|---|---|---|---|---|---|---|
Total Revenue | 1.11B | 1.14B | 1.16B | 1.22B | 1.22B | -0.4% | |
| Cost of Revenue | (349.10M) | (366.89M) | (389.33M) | (429.36M) | (415.97M) | -3.1% | |
Gross Profit | 756.50M | 769.82M | 769.73M | 790.27M | 799.07M | 1.1% | |
| Operating Expenses | |||||||
| Research & Development | (87.14M) | (92.49M) | (96.66M) | (99.50M) | (94.77M) | -4.8% | |
| Selling, General & Administrative | (339.00M) | (352.44M) | (393.32M) | (415.10M) | (452.42M) | 9.0% | |
| General & Administrative | (339.00M) | (352.44M) | (393.32M) | (415.10M) | (452.42M) | 9.0% | |
| Depreciation & Amortization | (101.07M) | (107.24M) | (111.71M) | (109.90M) | (97.36M) | -11.4% | |
Operating Income (EBIT) | 296.59M | 298.94M | 206.69M | 102.25M | 251.89M | 146.3% | |
| Non-Operating Items | |||||||
| Interest Income | 794.00K | 3.41M | 3.32M | 3.89M | — | -100.0% | |
| Interest Expense | (11.31M) | (11.21M) | (15.74M) | (8.51M) | (5.41M) | -36.5% | |
| Other Income/Expenses (Net) | 4.80M | 39.72M | -21.00M | -3.79M | -11.21M | 195.6% | |
Income Before Tax | 301.39M | 338.66M | 185.69M | 98.46M | 240.68M | 144.4% | |
| Income Tax Expense | (38.29M) | (53.22M) | (17.58M) | (25.06M) | (58.82M) | 134.7% | |
Net Income | 272.05M | 285.26M | 168.10M | 73.40M | 181.86M | 147.8% | |
| Per Share Metrics | |||||||
| Earnings Per Share (Basic) | $2 | $2 | $1 | $0 | $1 | 148.9% | |
| Weighted Avg Shares Outstanding | 156.88M | 157.18M | 157.71M | 157.52M | 155.96M | -1.0% | |
| Weighted Avg Shares Outstanding (Diluted) | 164.12M | 161.85M | 160.77M | 159.72M | 157.01M | -1.7% | |
EBITDA | 413.76M | 457.11M | 313.14M | 216.88M | 343.44M | 58.4% |
Explore TECH
TECH in the Healthcare
Large Cap